Oncimmune Holdings PLC ONC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 17.50
- Day Range
- GBX 16.50–17.80
- 52-Week Range
- GBX 9.35–31.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 1.30 Bil
- Volume/Avg
- 3,218 / 114,589
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.06%
Company Profile
Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection, and care of cancer. The company's operating segment is ImmunoINSIGHTS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 38
- Website
- https://www.oncimmune.com
Valuation
|
Metric
|
ONC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 10.77 |
Price/Cash Flow | — |
Price/Earnings
ONC
Financial Strength
|
Metric
|
ONC
|
|---|---|
Quick Ratio | 1.01 |
Current Ratio | 1.14 |
Interest Coverage | −9.43 |
Quick Ratio
ONC
Profitability
|
Metric
|
ONC
|
|---|---|
Return on Assets (Normalized) | −68.96% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −102.42% |
Return on Assets
ONC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hplqcpwjf | Ptrg | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cvjzyswm | Cfgpbh | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yghbkfxnf | Cgymk | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mhyxgvrd | Zdkznh | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Hqlwzmfjl | Jpvs | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Qqwfjdrs | Rsqq | $28.0 Bil | |||
| Moderna Inc
MRNA
| Kcqkhtmkj | Zsph | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Dxjwzqgc | Prf | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gwnkxfnh | Nxqsth | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Wxnfkqsxzs | Vmlxg | $12.6 Bil |
United States